Theratechnologies Stock Forecast for 2023 - 2025 - 2030
Updated on 05/04/2024
Theratechnologies Stock Forecast and Price Target
Theratechnologies's stock is projected to advance by 237.43% from the previous closing price if it reaches the average target of C$6.04 by the year's end, as two reputable analysts recently projected. This potential upside is calculated on a high-end estimate of C$8.00 and a low-end estimate of C$4.07. If you're looking for Theratechnologies (TH) stock information, you might also want to check out Bristol-Myers Squibb (NYSE:BMY).
237.43% Upside
Theratechnologies Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Theratechnologies's Price has grown, increasing from C$0.00 to C$0.00 – a growth of 100.00%. The next year looks promising for Theratechnologies, with analysts predicting Fair Value of C$1.89 – an increase of 100.00%. Over the next eight years, experts anticipate that Theratechnologies's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$149.27 | Buy/Sell | $174.55 | 13.89% |
| GSK Stock Forecast | GSK | Outperform |
12
|
£17.34 | Buy/Sell | £17.30 | 12.46% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$43.99 | Buy/Sell | $58.15 | 22.76% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$64.78 | Buy/Sell | $87.82 | 23.49% |
| PFIZER Stock Forecast | Pfizer | Outperform |
18
|
Rp4.21k | Buy/Sell | Rp4.53k | 17.20% |
Theratechnologies Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Theratechnologies's Revenue has grown, increasing from C$66.05M to C$81.76M – a growth of 23.79%. The next year looks promising for Theratechnologies, with analysts predicting Revenue of C$126.97M – an increase of 55.30%. Over the next ten years, experts anticipate that Theratechnologies's Revenue will grow at a rate of 897.39%.
.jpg)
Theratechnologies EBITDA Forecast for 2023 - 2025 - 2030
Theratechnologies's EBITDA has decreased In the last three years, from C$-9.88M to C$-5.70M – a 42.31% drop. In the following year, 2 experts forecast Theratechnologies's EBITDA will decrease by 233.33%, to C$7.60M. In 2030, professionals predict that Theratechnologies's EBITDA will decrease by 1671.75%, to C$89.59M.
Theratechnologies EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Theratechnologies's EBIT has seen a drop from C$-17.96M to C$-8.66M – a 51.78% decrease. According to 3 major analysts, Theratechnologies's EBIT will fall by 25.06% in the next year, reaching C$-6.49M. Professionals believe that By 2030, Theratechnologies's EBIT will fall to C$779.66M– a 9103.00% decrease from its current value.
Theratechnologies EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Theratechnologies's EPS has grown, increasing from C$-1.50 to C$0.00 – a growth of 100.00%. The next year looks promising for Theratechnologies, with analysts predicting EPS of C$-0.53 – an increase of 100.00%. Over the next eight years, experts anticipate that Theratechnologies's EPS will grow at a rate of 100.00%.
.jpg)